Exercise of Options

RNS Number : 2038F

Allergy Therapeutics PLC

20 April 2011

 



20 April 2011

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Exercise of Options

Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 15,000 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence in these shares on 21 April 2011. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company. The total number of shares in issue (inclusive of the above issue) is 310,771,614 ordinary shares of 0.1p each.

For further information

Allergy Therapeutics	[phone]
Manuel Llobet, Chief Executive Officer
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw
Financial Dynamics	[phone]
Ben Brewerton/ Susan Quigley

 

END

 

 

LISEALLNFSNFEFF